{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:29:40Z","timestamp":1787574580584,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":97,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In a previous work we demonstrated that pharmacological inhibition of wild type heat shock protein-110 (HSP110) could mimic an HSP110-inactive mutated phenotype reported to be associated with good prognosis in colorectal cancer (CRC) patients. We also demonstrated that HSP110 favored the formation of anti-inflammatory macrophages. We developed a second-generation HSP110 inhibitor called compound 7 (C7) through a hit-to-lead approach. Here, we deciphered its anti-cancer immune effect alone and associated with an anti-PD-L1\/PD-1 targeting therapy. The study (FACS, IHC, immunoblots, qPCR, shRNA approaches) included syngeneic CRC mouse models (CT26\/BALB\/c and MC38\/C57BL\/6), 3D human CRC (HCT 116, HT-29) spheroids and primary human macrophages and lymphocytes isolated from buffy coats, and tumor biopsies from 134 CRC patients of the Prodige-13 trial. C7 specifically inhibited HSP110, leading to significant tumor growth suppression in both mice bearing CT26 and MC38 tumors and our human spheroids models incorporating immune cells. C7 reshaped the tumor microenvironment by promoting a pro-inflammatory phenotype. Studies in 2D and 3D co-cultures of human macrophages and lymphocytes indicated that C7\u2019s effect involved a direct action on macrophages. C7 also induced the expression of the immune check point PD-L1 both in macrophages and tumor cells. Combining C7 and an anti-PD-L1 antibody resulted in a more effective tumor regression both in the immune check point inhibitor resistant CT26- and in the non-resistant MC38- tumor-bearing mouse model. Finally, we established a clinical relevance of HSP110 effect on macrophages by showing a correlation between HSP110 and the anti-inflammatory biomarker CD163 in a CRC patients\u2019 cohort. These findings demonstrate that pharmacological inhibition of HSP110 alters pro-tumoral macrophages and can overcome resistance to immune check point inhibitors.<\/jats:p>","DOI":"10.1038\/s41419-026-08826-7","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:33:49Z","timestamp":1779143629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combining PD-L1 blockade with a second-generation HSP110 inhibitor enhances antitumor immunity in colorectal cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Mar\u00eda Jimena","family":"Abrey-Recalde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavie","family":"Mialhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1883-0371","authenticated-orcid":false,"given":"Thi Khanh","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelmnim","family":"Radoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7850-5143","authenticated-orcid":false,"given":"Lisa","family":"Lagorgette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Belkaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adiilah","family":"Mamode Cassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Jacquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gobbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingrui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Derang\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lirussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtan","family":"Jego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3739-0930","authenticated-orcid":false,"given":"Xiang-Yang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-1992","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Hermetet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"8826_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1517\/13543784.2014.902442","volume":"23","author":"K Jhaveri","year":"2014","unstructured":"Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, et al. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs. 2014;23:611\u201328.","journal-title":"Expert Opin Investig Drugs"},{"key":"8826_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/or.2022.8443","volume":"49","author":"Z-N Li","year":"2023","unstructured":"Li Z-N, Luo Y. HSP90 inhibitors and cancer: prospects for use in targeted therapies (Review). Oncol Rep. 2023;49:6.","journal-title":"Oncol Rep"},{"key":"8826_CR3","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/nm.2457","volume":"17","author":"C Dorard","year":"2011","unstructured":"Dorard C, de Thonel A, Collura A, Marisa L, Svrcek M, Lagrange A, et al. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med. 2011;17:1283\u20139.","journal-title":"Nat Med"},{"key":"8826_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1053\/j.gastro.2013.10.054","volume":"146","author":"A Collura","year":"2014","unstructured":"Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, et al. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil\u2013based chemotherapy. Gastroenterology. 2014;146:401\u201311.e1.","journal-title":"Gastroenterology"},{"key":"8826_CR5","doi-asserted-by":"crossref","unstructured":"Kai M, Nakatsura T, Egami H, Senju S, Nishimura Y, Ogawa M. Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep. 2003;10:1777\u201382.","DOI":"10.3892\/or.10.6.1777"},{"key":"8826_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.semcancer.2021.07.014","volume":"86","author":"M Regimbeau","year":"2022","unstructured":"Regimbeau M, Abrey J, Vautrot V, Causse S, Gobbo J, Garrido C. Heat shock proteins and exosomes in cancer theranostics. Semin Cancer Biol. 2022;86:46\u201357.","journal-title":"Semin Cancer Biol"},{"key":"8826_CR7","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.3390\/cancers13174407","volume":"13","author":"J Hrudka","year":"2021","unstructured":"Hrudka J, Jel\u00ednkov\u00e1 K, Fi\u0161erov\u00e1 H, Mat\u011bj R, Mandys V, Waldauf P. Heat shock proteins 27, 70, and 110: expression and prognostic significance in colorectal cancer. Cancers. 2021;13:4407.","journal-title":"Cancers"},{"key":"8826_CR8","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1038\/onc.2016.403","volume":"36","author":"K Berthenet","year":"2016","unstructured":"Berthenet K, Bokhari AD, Lagrange A, Marcion G, Boudesco C, Causse S, et al. HSP110 promotes colorectal cancer growth through STAT3 activation. Oncogene. 2016;36:2328\u201336.","journal-title":"Oncogene"},{"key":"8826_CR9","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2014-07-590034","volume":"125","author":"R Zappasodi","year":"2015","unstructured":"Zappasodi R, Ruggiero G, Guarnotta C, Tortoreto M, Tringali C, Cavan\u00e8 A, et al. HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. Blood. 2015;125:1768\u201371.","journal-title":"Blood"},{"key":"8826_CR10","doi-asserted-by":"publisher","first-page":"e1170264","DOI":"10.1080\/2162402X.2016.1170264","volume":"5","author":"K Berthenet","year":"2016","unstructured":"Berthenet K, Boudesco C, Collura A, Svrcek M, Richaud S, Hammann A, et al. Extracellular HSP110 skews macrophage polarization in colorectal cancer. Oncoimmunology. 2016;5:e1170264\u2013e.","journal-title":"Oncoimmunology"},{"key":"8826_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1182\/blood-2017-12-819706","volume":"132","author":"C Boudesco","year":"2018","unstructured":"Boudesco C, Verhoeyen E, Martin L, Chassagne-Clement C, Salmi L, Mhaidly R, et al. HSP110 sustains chronic NF-\u03baB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Blood. 2018;132:510\u201320.","journal-title":"Blood"},{"key":"8826_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/jnci\/djx136","volume":"110","author":"L Marisa","year":"2017","unstructured":"Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, et al. The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors. JNCI J Natl Cancer Inst. 2017;110:68\u201377.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"8826_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1053\/j.gastro.2021.05.007","volume":"161","author":"T Ratovomanana","year":"2021","unstructured":"Ratovomanana T, Cohen R, Svrcek M, Renaud F, Cervera P, Siret A, et al. Performance of next-generation sequencing for the detection of microsatellite instability in colorectal cancer with deficient DNA mismatch repair. Gastroenterology. 2021;161:814\u201326.e7.","journal-title":"Gastroenterology"},{"key":"8826_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00018-022-04293-3","volume":"79","author":"K Noel","year":"2022","unstructured":"Noel K, Bokhari AD, Bertrand R, Renaud F, Bourgoin P, Cohen R, et al. Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice. Cell Mol Life Sci. 2022;79:332.","journal-title":"Cell Mol Life Sci"},{"key":"8826_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41418-019-0343-4","volume":"27","author":"GJ Gozzi","year":"2020","unstructured":"Gozzi GJ, Gonzalez D, Boudesco C, Dias AMM, Gotthard G, Uyanik B, et al. Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy. Cell Death Differ. 2020;27:117\u201329.","journal-title":"Cell Death Differ"},{"key":"8826_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmcr.2023.100103","volume":"7","author":"L Xu","year":"2023","unstructured":"Xu L, Wang Y, He X, Gao Y, Lirussi F, Zhou Y, et al. Discovery of second generation heat shock protein 110 (HSP110) inhibitors for potential treatment of colorectal cancer. Eur J Medicinal Chem Rep. 2023;7:100103.","journal-title":"Eur J Medicinal Chem Rep"},{"key":"8826_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.dld.2015.03.021","volume":"47","author":"C Lepage","year":"2015","unstructured":"Lepage C, Phelip J-M, Cany L, Faroux R, Manfredi S, Ain J-F, et al. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial. Digest Liver Dis. 2015;47:529\u201331.","journal-title":"Digest Liver Dis"},{"key":"8826_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0046-8177(95)90060-8","volume":"26","author":"H Goulding","year":"1995","unstructured":"Goulding H, Pinder S, Cannon P, Pearson D, Nicholson R, Snead D, et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol. 1995;26:291\u20134.","journal-title":"Hum Pathol"},{"key":"8826_CR19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","volume":"26","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, et al. Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin Cancer Res. 2020;26:970\u20137.","journal-title":"Clin Cancer Res"},{"key":"8826_CR20","doi-asserted-by":"publisher","first-page":"e1433981","DOI":"10.1080\/2162402X.2018.1433981","volume":"7","author":"M Dosset","year":"2018","unstructured":"Dosset M, Vargas TR, Lagrange A, Boidot R, V\u00e9gran F, Roussey A, et al. PD-1\/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology. 2018;7:e1433981\u2013e.","journal-title":"Oncoimmunology"},{"key":"8826_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.canlet.2010.10.014","volume":"332","author":"G Jego","year":"2013","unstructured":"Jego G, Hazoum\u00e9 A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett. 2013;332:275\u201385.","journal-title":"Cancer Lett"},{"key":"8826_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.humpath.2017.08.001","volume":"67","author":"K-J Kim","year":"2017","unstructured":"Kim K-J, Lee TH, Kim JH, Cho N-Y, Kim WH, Kang GH. Deletion in HSP110 T17: correlation with wild-type HSP110 expression and prognostic significance in microsatellite-unstable advanced gastric cancers. Hum Pathol. 2017;67:109\u201318.","journal-title":"Hum Pathol"},{"key":"8826_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29363-9","volume":"13","author":"R Alimohammadi","year":"2023","unstructured":"Alimohammadi R, Mahmoodi Chalbatani G, Alimohammadi M, Ghaffari-Nazari H, Rahimi A, Mortaz E, et al. Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model. Sci Rep. 2023;13:2472.","journal-title":"Sci Rep"},{"key":"8826_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, et al. Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22:58.","journal-title":"Mol Cancer"},{"key":"8826_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107126","volume":"202","author":"Q Lv","year":"2024","unstructured":"Lv Q, Zhang Y, Gao W, Wang J, Hu Y, Yang H, et al. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer. Pharmacol Res. 2024;202:107126.","journal-title":"Pharmacol Res"},{"key":"8826_CR26","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1158\/1078-0432.CCR-21-0903","volume":"27","author":"SA Weiss","year":"2021","unstructured":"Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, et al. A phase I study of APX005M and cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or non-small cell lung cancer resistant to anti-PD-1\/PD-L1. Clin Cancer Res. 2021;27:4757\u201367.","journal-title":"Clin Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08826-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08826-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08826-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:07:50Z","timestamp":1787573270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08826-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8826"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08826-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"753"}}